(18)F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma

Documenti analoghi

• Integrin-targeted quantitative optoacoustic imaging with MRI correlation for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma
  di: Kazmierczak, Philipp M., et al.
  Pubblicazione: (2018)
• Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.
  di: Ralf Stefan Eschbach, et al.
  Pubblicazione: (2017-01-01)
• Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation
  di: Eschbach, Ralf Stefan, et al.
  Pubblicazione: (2017)
• (68)Ga-TRAP-(RGD)(3) Hybrid Imaging for the In Vivo Monitoring of α(v)ß(3)-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer
  di: Kazmierczak, Philipp M., et al.
  Pubblicazione: (2016)
• Correlation of Perfusion MRI and (18)F-FDG PET Imaging Biomarkers for Monitoring Regorafenib Therapy in Experimental Colon Carcinomas with Immunohistochemical Validation
  di: Eschbach, Ralf S., et al.
  Pubblicazione: (2015)